These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307 [TBL] [Abstract][Full Text] [Related]
6. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. Duckworth W; Davis SN J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554 [TBL] [Abstract][Full Text] [Related]
7. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus. Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465 [TBL] [Abstract][Full Text] [Related]
8. Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Chatterjee S; Tringham JR; Davies MJ Expert Opin Pharmacother; 2006 Jul; 7(10):1357-71. PubMed ID: 16805721 [TBL] [Abstract][Full Text] [Related]
9. Insulin glargine in the treatment of type 1 and type 2 diabetes. Barnett AH Vasc Health Risk Manag; 2006; 2(1):59-67. PubMed ID: 17319470 [TBL] [Abstract][Full Text] [Related]
10. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Rosenstock J; Park G; Zimmerman J; Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511 [TBL] [Abstract][Full Text] [Related]
11. A randomized cross-over trial to identify the optimal use of insulin glargine in prepubertal children using a three-times daily insulin regimen. Fröhlich-Reiterer EE; Ong KK; Regan F; Salzano G; Acerini CL; Dunger DB Diabet Med; 2007 Dec; 24(12):1406-11. PubMed ID: 18042082 [TBL] [Abstract][Full Text] [Related]
12. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810 [TBL] [Abstract][Full Text] [Related]
13. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605 [TBL] [Abstract][Full Text] [Related]
14. Insulin Glargine: a review 8 years after its introduction. Goykhman S; Drincic A; Desmangles JC; Rendell M Expert Opin Pharmacother; 2009 Mar; 10(4):705-18. PubMed ID: 19284367 [TBL] [Abstract][Full Text] [Related]
15. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Peterson GE Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343 [TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996 [TBL] [Abstract][Full Text] [Related]
17. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Dunn CJ; Plosker GL; Keating GM; McKeage K; Scott LJ Drugs; 2003; 63(16):1743-78. PubMed ID: 12904090 [TBL] [Abstract][Full Text] [Related]
18. [An update on multiple insulin injection therapy in type 1 and 2 diabetes]. Varanauskiene E; Varanauskaite I; Ceponis J Medicina (Kaunas); 2006; 42(9):770-9. PubMed ID: 17028476 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018 [TBL] [Abstract][Full Text] [Related]
20. [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy]. Pesić M; Zivić S; Radenković S; Velojić M; Dimić D; Antić S Vojnosanit Pregl; 2007 Apr; 64(4):247-52. PubMed ID: 17580534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]